Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting

Schedule of certain segment information

The following table includes certain segment information for the periods presented (in thousands):

	Three Months Ended March 31,
	2026		2025
Grant and award revenue	$	789	$	491
Operating expenses
Research and development expenses:
AP-PA02: Non-Cystic Fibrosis Bronchiectasis		(26)		(440)
AP-PA02: Cystic Fibrosis		-		11
AP-SA02: Bacteremia		115		652
AP-SA02: Prosthetic Joint Infection		-		1
Expenses not allocated by projects		894		520
Total external research and development expenses		983		744
Research and development personnel expenses		2,625		2,313
Other research and development expenses		2,503		2,372
Total research and development expenses		6,111		5,429
General and administrative expenses:
General and administrative personnel expenses		1,462		1,401
Other general and administrative expenses		2,001		1,852
Total general and administrative expenses		3,463		3,253
Total operating expenses		9,574		8,682
Operating loss		(8,785)		(8,191)
Other income (expense), net		(106,561)		1,660
Net loss	$	(115,346)	$	(6,531)